Aurobindo Pharma Limited (AUROPHARMA)

Healthcare · Pharmaceuticals & Biotechnology · NSE · Updated 30 July 2026

By StockFin Research Team • AI-Assisted Analysis • Source: BSE/NSE Filings

₹1,576.3 ↑ 36.12% (1Y)

🎯 Key Takeaways

Aurobindo Pharma is transitioning from a pure-play API manufacturer to a vertically integrated player with strategic expansion into contract research and renewable energy, evidenced by its acquisition of A1 Biochem Group and investment in solar infrastructure. The company is in a growth phase, leveraging its strong API foundation to diversify into higher-margin CRDMO services and sustainability initiatives, while maintaining robust profitability trends.
Revenue grew 2.3% QoQ to ₹7,979 in Q3FY25.
⚠️ Integration risk from the A1 Biochem acquisition, which may face delays or operational challenges in merging US-based CRO operations with Aurobindo’s

Market Cap

₹87,806

P/E Ratio

25.3

Div Yield

0.00%

Promoter

0.0%

✨ Ask AI About AUROPHARMA 📊 Interactive Charts

📖 The Story

Aurobindo Pharma is transitioning from a pure-play API manufacturer to a vertically integrated player with strategic expansion into contract research and renewable energy, evidenced by its acquisition of A1 Biochem Group and investment in solar infrastructure. The company is in a growth phase, leveraging its strong API foundation to diversify into higher-margin CRDMO services and sustainability initiatives, while maintaining robust profitability trends.

📰 What's Happening

In June 2026, Aurobindo Pharma completed the acquisition of a 26% stake in Swarnaakshu Solar Power Private Limited and entered into a solar power purchase agreement, marking its entry into renewable energy with an initial investment of Rs. 52 lakhs. Simultaneously, its subsidiary Apitoria Pharma agreed to acquire 80% ownership in US-based A1 Biochem Group for USD 17 million, adding a CRO with INR 1,024.4 Mn turnover to enhance its CRDMO platform. Management indicated a 90-120 day timeline to close the A1 Biochem acquisition, signaling active M&A-driven expansion beyond traditional API manufacturing.

Source: Stock Announcements

📊 Quarterly Results (₹ Cr)

Metric	Q4FY23	Q1FY24	Q2FY24	Q3FY24	Q4FY24	Q1FY25	Q2FY25	Q3FY25
Revenue	6,473	6,851	7,219	7,352	7,580	7,567	7,796	7,979
Operating Profit	1,137	1,198	1,560	1,764	1,686	1,841	1,702	1,735
OPM %	15.5%	16.8%	19.0%	21.8%	22.1%	21.4%	20.1%	19.8%
Net Profit	506	570	752	940	907	918	817	846
EPS	₹8.64	₹9.74	₹12.83	₹16.04	₹15.51	₹15.69	₹14.00	₹14.56

Aurobindo Pharma has demonstrated consistent top-line growth and stable operating margins over the past eight quarters, with Q3FY25 revenue of ₹7,979 Crore reflecting a 9% YoY increase from Q3FY24. Operating margins have remained resilient at 19.8% in Q3FY25, supported by cost discipline despite macroeconomic pressures. Net profit and EPS trends show sequential improvement, with Q3FY25 EPS at ₹14.56, up from ₹12.83 in the same quarter last year, indicating effective operational scaling and margin management.

🔮 Management Outlook & What's Next

Management has not provided explicit forward guidance in the latest filings, but strategic actions suggest a focus on scaling CRDMO capabilities and renewable energy investments as growth levers. The acquisition of A1 Biochem Group is expected to contribute to the CRDMO platform within 90-120 days post-closing, potentially enhancing contract services revenue. The solar initiative reflects a broader sustainability agenda, though near-term financial impact is expected to be limited.

Extracted from official company announcements. Not StockFin.ai's opinion.

⚖️ Peer Comparison — Pharmaceuticals & Biotechnology

Company	MCap (₹ Cr)	P/E	ROCE	ROE	D/E
Sun Pharmaceutical Industries Limited	4.51 L Cr	41.3	20.3%	15.1%	0.03
Divi's Laboratories Limited	1.79 L Cr	72.4	22.1%	16.6%	0.00
Torrent Pharmaceuticals Limited	1.49 L Cr	80.1	—	—	—
Cipla Limited	1.16 L Cr	25.4	19.4%	14.6%	0.00
Dr. Reddy's Laboratories Limited	1.12 L Cr	20.0	19.7%	16.6%	0.12
Lupin Limited	1.04 L Cr	36.2	—	—	—
Mankind Pharma Limited	1.03 L Cr	49.2	—	—	—
Zydus Lifesciences Limited	1.02 L Cr	22.5	—	—	—
Aurobindo Pharma Limited	87,806	25.3	—	—	—
Laurus Labs Limited	71,455	356.8	—	—	—

🔗 Peer Stock Analyses

SUNPHARMA DIVISLAB TORNTPHARM CIPLA DRREDDY

⚠️ Risk Factors

1. Integration risk from the A1 Biochem acquisition, which may face delays or operational challenges in merging US-based CRO operations with Aurobindo’s existing API business. 2. Execution risk in scaling CRDMO services, where management has limited prior experience. 3. Renewable energy investments may divert focus and capital without immediate returns, potentially impacting near-term profitability. 4. Regulatory and pricing pressures in the API market remain structural headwinds despite margin resilience.

📋 Recent Filings

🧠 Analyst's Read

Aurobindo Pharma is actively reshaping its growth trajectory through targeted acquisitions and sustainability initiatives, with financial performance supporting its operational stability. Investors should monitor the successful integration of A1 Biochem and the scalability of CRDMO services as key catalysts, while remaining cautious of execution risks in new verticals.

Based on filing content and financial data. Not a recommendation.

Read the full analysis

Quarterly trends, balance sheet, cash flow, peer comparison, and AI insights — sign up free to unlock.

2 free AI queries per day.

✨ Deep Dive with AI on AUROPHARMA

Data sourced from stock announcements. Analysis generated by StockFin.ai.
For informational purposes only — not investment advice. Updated 2026-07-30.

Editorial & Data Transparency Notice

This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.

📡 Get AI alerts when AUROPHARMA files new disclosures

Track AUROPHARMA filings, board meetings, and corporate actions. Free email alerts at 5 PM.

Track AUROPHARMA — Free

Free account · 2 AI queries/day